Invesco DB Agriculture Fund vs Zoetis Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.37 (market cap $1.32B), while Zoetis Inc trades at $73.88 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 22.9× Invesco DB Agriculture Fund's market cap, and Zoetis Inc pays a 2.9% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Zoetis Inc for 70 Days on average.
| DBA | ZTS | |
|---|---|---|
Market Cap | $1.32B | $30.20B |
Volume | 771,657 | 6,175,327 |
52-Week High | $29.49 | $147.53 |
52-Week Low | $25.44 | $69.09 |
Typical Hold Time | 24 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong year-to-date performance with 12.4% returns matching the S&P 500. The technical outlook remains bullish with moving averages signaling strength and ADX indicators confirming trend momentum. Recent news highlights agricultural ETF outperformance driven by weather risks, geopolitical tensions, and strong global demand for commodities.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and climate factors, though the 0.85% expense ratio and commodity volatility present risks. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish technical consolidation near all-time highs since 2020.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →